Third Rock, Arch, J&J Pump $100M into Rapport to Develop Precision Neuro Drugs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Septerna, Backed by Third Rock and RA, Gets $150M for GPCR Drug Discovery
Third Rock Raises $1.1B Fund, Sticks With Its Knitting in a Downturn
MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell
Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS